INVESTBOARDLog in
Healthcare · Healthcare Plans · US

Progyny Inc PGNY

$35.95 · close of Nov 9, 2026
AI score · Solid · analysis Oct 16, 2025
6.9 of 10

Management and Optionality hold this up; Risk is the soft spot.

Moat6.0
Management8.0
Valuation7.0
Risk · 10 = lowest6.0
Business model7.0
Optionality8.0
Fair value
AI fair value
—
Base case
—
the single most likely path
Analyst consensus
$35.25
12 analysts · 12-month target
Price
$35.95
The business

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Last report Nov 4, 2026

Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.

Start the thirty days · no card
General investment analysis · not personalized advice · the figures carry their dates